As of 2024-12-13, the EV/EBITDA ratio of Pacific Biosciences of California Inc (PACB) is -6.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PACB's latest enterprise value is 1,375.21 mil USD. PACB's TTM EBITDA according to its financial statements is -214.31 mil USD. Dividing these 2 quantities gives us the above PACB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 18.8x - 20.6x | 20.4x |
| Forward P/E multiples | 19.1x - 24.1x | 21.9x |
| Fair Price | (17.95) - (19.07) | (19.51) |
| Upside | -978.0% - -1032.3% | -1053.9% |
| Date | EV/EBITDA |
| 2024-12-12 | -6.42 |
| 2024-12-11 | -6.70 |
| 2024-12-10 | -6.79 |
| 2024-12-09 | -6.59 |
| 2024-12-06 | -6.40 |
| 2024-12-05 | -6.33 |
| 2024-12-04 | -6.46 |
| 2024-12-03 | -6.14 |
| 2024-12-02 | -6.27 |
| 2024-11-29 | -6.24 |
| 2024-11-27 | -6.05 |
| 2024-11-26 | -6.07 |
| 2024-11-25 | -6.17 |
| 2024-11-22 | -6.10 |
| 2024-11-21 | -6.07 |
| 2024-11-20 | -6.00 |
| 2024-11-19 | -6.00 |
| 2024-11-18 | -5.81 |
| 2024-11-15 | -5.84 |
| 2024-11-14 | -6.17 |
| 2024-11-13 | -6.33 |
| 2024-11-12 | -6.62 |
| 2024-11-11 | -6.95 |
| 2024-11-08 | -6.74 |
| 2024-11-07 | -6.93 |
| 2024-11-06 | -7.19 |
| 2024-11-05 | -7.06 |
| 2024-11-04 | -7.01 |
| 2024-11-01 | -6.92 |
| 2024-10-31 | -6.58 |
| 2024-10-30 | -6.56 |
| 2024-10-29 | -6.44 |
| 2024-10-28 | -6.15 |
| 2024-10-25 | -6.07 |
| 2024-10-24 | -6.00 |
| 2024-10-23 | -6.04 |
| 2024-10-22 | -6.10 |
| 2024-10-21 | -6.15 |
| 2024-10-18 | -6.33 |
| 2024-10-17 | -6.23 |
| 2024-10-16 | -6.44 |
| 2024-10-15 | -6.49 |
| 2024-10-14 | -6.42 |
| 2024-10-11 | -6.33 |
| 2024-10-10 | -5.78 |
| 2024-10-09 | -5.86 |
| 2024-10-08 | -5.96 |
| 2024-10-07 | -5.98 |
| 2024-10-04 | -6.00 |
| 2024-10-03 | -5.89 |